Enterome Extends Its Microbiome Platform

The French firm has partners for its diagnostics, wants to spin out a "stool banking" company, and might follow other microbiome start-ups into drug discovery to explore the connections between our bugs and our immune system.

It took a decade for the sequencing of the human genome to yield insights that filtered into therapeutic applications. So when similar work began a few years ago to decode the human microbiome, the trillions of microbes that live in and on the human body, wisdom held that it could take far longer to translate into help for patients. The slow flow of venture money into the area has reinforced that notion. (See[A#2012900157].)

"So far the momentum isn't remarkable," says Isabelle de Cremoux, CEO of diversified venture firm Seventure Partners. "Look at the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Roche Keen To Cut Out The Middle Men On US Pricing

 
• By 

The Swiss giant has been talking to the US government about selling medicines directly to patients.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.